Anieta M Sieuwerts

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7823081/publications.pdf

Version: 2024-02-01

135 papers	17,273 citations	34493 54 h-index	16791 127 g-index
138 all docs	138 docs citations	138 times ranked	26880 citing authors

#	Article	IF	Citations
1	The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer. BMC Cancer, 2022, 22, 165.	1.1	8
2	A pipeline for copy number profiling of single circulating tumour cells to assess intrapatient tumour heterogeneity. Molecular Oncology, 2022, 16, 2981-3000.	2.1	6
3	Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests. Oncogene, 2022, 41, 3498-3506.	2.6	9
4	Detection of tumor-derived extracellular vesicles in plasma from patients with solid cancer. BMC Cancer, 2021, 21, 315.	1.1	18
5	Prospective Evaluation of a Circulating Tumor Cell Sensitivity Profile to Predict Response to Cisplatin Chemotherapy in Metastatic Breast Cancer Patients. Frontiers in Oncology, 2021, 11, 697572.	1.3	0
6	Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells. European Journal of Cancer, 2021, 150, 179-189.	1.3	47
7	Interconnectivity between molecular subtypes and tumor stage in colorectal cancer. BMC Cancer, 2020, 20, 850.	1.1	14
8	Plasticity of Lgr5-Negative Cancer Cells Drives Metastasis in Colorectal Cancer. Cell Stem Cell, 2020, 26, 569-578.e7.	5.2	180
9	ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen. Cancers, 2020, 12, 802.	1.7	20
10	Optimization of Pancreatic Juice Collection: A First Step Toward Biomarker Discovery and Early Detection of Pancreatic Cancer. American Journal of Gastroenterology, 2020, 115, 2103-2108.	0.2	14
11	APOBEC3B Gene Expression in Ductal Carcinoma In Situ and Synchronous Invasive Breast Cancer. Cancers, 2019, 11, 1062.	1.7	9
12	Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel. Cancers, 2019, 11, 1212.	1.7	21
13	Generation of in situ sequencing based OncoMaps to spatially resolve gene expression profiles of diagnostic and prognostic markers in breast cancer. EBioMedicine, 2019, 48, 212-223.	2.7	29
14	Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer. European Journal of Cancer, 2019, 121, 48-54.	1.3	20
15	The circular RNome of primary breast cancer. Genome Research, 2019, 29, 356-366.	2.4	85
16	Proteome-wide onco-proteogenomic somatic variant identification in ER-positive breast cancer. Clinical Biochemistry, 2019, 66, 63-75.	0.8	3
17	AR splice variants in circulating tumor cells of patients with castrationâ€resistant prostate cancer: relation with outcome to cabazitaxel. Molecular Oncology, 2019, 13, 1795-1807.	2.1	23
18	Partially methylated domains are hypervariable in breast cancer and fuel widespread CpG island hypermethylation. Nature Communications, 2019, 10, 1749.	5.8	46

#	Article	IF	Citations
19	Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer. International Journal of Cancer, 2019, 145, 1083-1089.	2.3	27
20	An Optimized Workflow to Evaluate Estrogen Receptor Gene Mutations in Small Amounts of Cell-Free DNA. Journal of Molecular Diagnostics, 2019, 21, 123-137.	1.2	15
21	PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer. Endocrine-Related Cancer, 2019, 26, 471-482.	1.6	17
22	An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7 mRNA Expression in Circulating Tumor Cells. Journal of Molecular Diagnostics, 2018, 20, 316-325.	1.2	15
23	T lymphocytes facilitate brain metastasis of breast cancer by inducing Guanylate-Binding Protein 1 expression. Acta Neuropathologica, 2018, 135, 581-599.	3.9	63
24	Confirmation of a metastasis-specific microRNA signature in primary colon cancer. Scientific Reports, 2018, 8, 5242.	1.6	33
25	Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients. Molecular Oncology, 2018, 12, 48-57.	2.1	52
26	Analysis of clonal expansions through the normal and premalignant human breast epithelium reveals the presence of luminal stem cells. Journal of Pathology, 2018, 244, 61-70.	2.1	13
27	Association of microRNA-7 and its binding partner CDR1-AS with the prognosis and prediction of 1st-line tamoxifen therapy in breast cancer. Scientific Reports, 2018, 8, 9657.	1.6	32
28	Gene length corrected trimmed mean of M-values (GeTMM) processing of RNA-seq data performs similarly in intersample analyses while improving intrasample comparisons. BMC Bioinformatics, 2018, 19, 236.	1.2	105
29	Dendritic Cells Actively Limit Interleukin-10 Production Under Inflammatory Conditions via DC-SCRIPT and Dual-Specificity Phosphatase 4. Frontiers in Immunology, 2018, 9, 1420.	2.2	16
30	Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects. Clinical Cancer Research, 2018, 24, 6277-6287.	3.2	53
31	MicroRNA expression in pre-treatment plasma of patients with benign breast diseases and breast cancer. Oncotarget, 2018, 9, 24335-24346.	0.8	11
32	Low Tumor Mitochondrial DNA Content Is Associated with Better Outcome in Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy. Clinical Cancer Research, 2017, 23, 4735-4743.	3.2	14
33	A Systematic Analysis of Oncogenic Gene Fusions in Primary Colon Cancer. Cancer Research, 2017, 77, 3814-3822.	0.4	76
34	Gene Expression Differences between Ductal Carcinoma in Situ with and without Progression to Invasive Breast Cancer. American Journal of Pathology, 2017, 187, 1648-1655.	1.9	23
35	Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer. Scientific Reports, 2017, 7, 2099.	1.6	33
36	HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nature Medicine, 2017, 23, 517-525.	15.2	769

#	Article	IF	Citations
37	Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. Oncogene, 2017, 36, 2737-2749.	2.6	34
38	Genomic Evolution of Breast Cancer Metastasis and Relapse. Cancer Cell, 2017, 32, 169-184.e7.	7.7	534
39	High mRNA expression of splice variant SYK short correlates with hepatic disease progression in chemonaive lymph node negative colon cancer patients. PLoS ONE, 2017, 12, e0185607.	1.1	14
40	Prospects of Targeting the Gastrin Releasing Peptide Receptor and Somatostatin Receptor 2 for Nuclear Imaging and Therapy in Metastatic Breast Cancer. PLoS ONE, 2017, 12, e0170536.	1.1	8
41	Progressive APOBEC3B mRNA expression in distant breast cancer metastases. PLoS ONE, 2017, 12, e0171343.	1.1	31
42	The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer. PLoS ONE, 2016, 11, e0161731.	1.1	15
43	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature, 2016, 534, 47-54.	13.7	1,760
44	mRNA expression profiles of colorectal liver metastases as a novel biomarker for early recurrence after partial hepatectomy. Molecular Oncology, 2016, 10, 1542-1550.	2.1	9
45	The topography of mutational processes in breast cancer genomes. Nature Communications, 2016, 7, 11383.	5.8	235
46	Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. Nature Communications, 2016, 7, 12910.	5.8	119
47	The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. Science Advances, 2016, 2, e1601737.	4.7	175
48	Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor. Neoplasia, 2016, 18, 647-653.	2.3	44
49	GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease. Cancer Letters, 2016, 376, 104-109.	3.2	22
50	An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients. BMC Cancer, 2016, 16, 123.	1.1	25
51	APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma. Clinical Cancer Research, 2016, 22, 4746-4755.	3.2	59
52	Molecular characteristics of circulating tumor cells resemble the liver metastasis more closely than the primary tumor in metastatic colorectal cancer. Oncotarget, 2016, 7, 59058-59069.	0.8	37
53	Mitochondrial DNA content in breast cancer: Impact on in vitro and in vivo phenotype and patient prognosis. Oncotarget, 2016, 7, 29166-29176.	0.8	33
54	A Method to Correlate mRNA Expression Datasets Obtained from Fresh Frozen and Formalin-Fixed, Paraffin-Embedded Tissue Samples: A Matter of Thresholds. PLoS ONE, 2015, 10, e0144097.	1.1	6

#	Article	IF	Citations
55	Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. Molecular Cancer Therapeutics, 2015, 14, 821-827.	1.9	49
56	mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients. Molecular Oncology, 2015, 9, 920-932.	2.1	37
57	Integrative Analysis of Genomics and Proteomics Data on Clinical Breast Cancer Tissue Specimens Extracted with Acid Guanidinium Thiocyanateâ€“Phenolâ€“Chloroform. Journal of Proteome Research, 2015, 14, 1627-1636.	1.8	17
58	DC-SCRIPT is a novel regulator of the tumor suppressor gene CDKN2B and induces cell cycle arrest in ERÎ±-positive breast cancer cells. Breast Cancer Research and Treatment, 2015, 149, 693-703.	1.1	16
59	Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells. European Urology, 2015, 68, 939-945.	0.9	223
60	Proper genomic profiling of (BRCA1â€mutated) basalâ€like breast carcinomas requires prior removal of tumor infiltrating lymphocytes. Molecular Oncology, 2015, 9, 877-888.	2.1	16
61	Decreased expression of ABAT and STC2 hallmarks ERâ€positive inflammatory breast cancer and endocrine therapy resistance in advanced disease. Molecular Oncology, 2015, 9, 1218-1233.	2.1	64
62	Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer. Cancer Letters, 2015, 362, 36-44.	3.2	41
63	The Influence of Tissue Procurement Procedures on RNA Integrity, Gene Expression, and Morphology in Porcine and Human Liver Tissue. Biopreservation and Biobanking, 2015, 13, 200-206.	0.5	23
64	In Vitro and In Vivo Application of Radiolabeled Gastrin-Releasing Peptide Receptor Ligands in Breast Cancer. Journal of Nuclear Medicine, 2015, 56, 752-757.	2.8	49
65	Clinical Relevance of Targeting the Gastrin-Releasing Peptide Receptor, Somatostatin Receptor 2, or Chemokine C-X-C Motif Receptor 4 in Breast Cancer for Imaging and Therapy. Journal of Nuclear Medicine, 2015, 56, 1487-1493.	2.8	30
66	Circulating tumour cells and lung microvascular tumour cell retention in patients with metastatic breast and cervical cancer. Cancer Letters, 2015, 356, 872-879.	3.2	28
67	Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients. Annals of Oncology, 2015, 26, 510-516.	0.6	46
68	Shotgun Proteomics on Tissue Specimens Extracted with Acid Guanidinium-Thiocyanate-Phenol-Chloroform. Methods in Molecular Biology, 2015, 1293, 115-122.	0.4	4
69	Comparative Proteome Analysis Revealing an 11-Protein Signature for Aggressive Triple-Negative Breast Cancer. Journal of the National Cancer Institute, 2014, 106, djt376.	3.0	77
70	Evaluation of the ability of adjuvant tamoxifenâ€benefit gene signatures to predict outcome of hormoneâ€naive estrogen receptorâ€positive breast cancer patients treated with tamoxifen in the advanced setting. Molecular Oncology, 2014, 8, 1679-1689.	2.1	18
71	Functional Ex Vivo Assay to Select Homologous Recombinationâ€“Deficient Breast Tumors for PARP Inhibitor Treatment. Clinical Cancer Research, 2014, 20, 4816-4826.	3.2	144
72	Elevated APOBEC3B Correlates with Poor Outcomes for Estrogen-Receptor-Positive Breast Cancers. Hormones and Cancer, 2014, 5, 405-413.	4.9	140

#	Article	IF	Citations
73	LAMP3 is involved in tamoxifen resistance in breast cancer cells through the modulation of autophagy. Endocrine-Related Cancer, 2014, 21, 101-112.	1.6	82
74	Gene expression profiles of primary tumors versus circulating tumor cells in metastatic breast cancer.. Journal of Clinical Oncology, 2014, 32, 11017-11017.	0.8	0
75	<scp>KRAS</scp> and <scp>BRAF</scp> mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. International Journal of Cancer, 2013, 133, 130-141.	2.3	128
76	Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer. Breast Cancer Research and Treatment, 2013, 138, 47-57.	1.1	110
77	CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Research, 2013, 23, 1446-1461.	2.4	526
78	Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting. British Journal of Cancer, 2013, 108, 1358-1367.	2.9	148
79	KLF6-SV1 Drives Breast Cancer Metastasis and Is Associated with Poor Survival. Science Translational Medicine, 2013, 5, 169ra12.	5.8	70
80	Allele-Specific, Non-Extendable Primer Blocker PCR (AS-NEPB-PCR) for DNA Mutation Detection in Cancer. Journal of Molecular Diagnostics, 2013, 15, 62-69.	1.2	35
81	The challenge of gene expression profiling in heterogeneous clinical samples. Methods, 2013, 59, 47-58.	1.9	18
82	CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations. Oncotarget, 2013, 4, 1748-1762.	0.8	169
83	A combined EpCAM and MCAM circulating tumor cell (CTC) CellSearch enrichment to improve CTC capture rate in stage II/III breast cancer: A Dutch Breast Cancer Trialists' Group (BOOG) side study.. Journal of Clinical Oncology, 2013, 31, e22106-e22106.	0.8	1
84	mRNA expression profiles in circulating tumor cells (CTCs) of patients with metastatic breast cancer (MBC) treated with aromatase inhibitors (AI).. Journal of Clinical Oncology, 2013, 31, 11045-11045.	0.8	0
85	High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes. Breast Cancer Research, 2012, 14, R123.	2.2	38
86	CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypes. Cancer Letters, 2012, 319, 49-55.	3.2	48
87	BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib. British Journal of Cancer, 2012, 107, 947-955.	2.9	61
88	The Life History of 21 Breast Cancers. Cell, 2012, 149, 994-1007.	13.5	1,249
89	Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes. Breast Cancer Research and Treatment, 2012, 132, 439-448.	1.1	37
90	Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes. Breast Cancer Research and Treatment, 2012, 133, 843-851.	1.1	46

#	Article	IF	Citations
91	High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Research and Treatment, 2012, 133, 937-947.	1.1	65
92	A new approach for rapid and reliable enumeration of circulating endothelial cells in patients. Journal of Thrombosis and Haemostasis, 2012, 10, 931-939.	1.9	48
93	Multiplex Molecular Analysis of CTCs. Recent Results in Cancer Research, 2012, 195, 125-140.	1.8	14
94	Hormone replacement therapy dependent changes in breast cancerâ€related gene expression in breast tissue of healthy postmenopausal women. Molecular Oncology, 2011, 5, 504-516.	2.1	7
95	Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients. Expert Review of Molecular Diagnostics, 2011, 11, 259-275.	1.5	70
96	Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer. Breast Cancer Research and Treatment, 2011, 125, 387-394.	1.1	46
97	Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. Breast Cancer Research and Treatment, 2011, 127, 33-41.	1.1	110
98	MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Research and Treatment, 2011, 127, 43-51.	1.1	127
99	Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes. Breast Cancer Research and Treatment, 2011, 128, 23-30.	1.1	83
100	mRNA and microRNA Expression Profiles in Circulating Tumor Cells and Primary Tumors of Metastatic Breast Cancer Patients. Clinical Cancer Research, 2011, 17, 3600-3618.	3.2	207
101	Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer. British Journal of Cancer, 2010, 103, 1284-1291.	2.9	111
102	Overexpression of Colligin 2 in Glioma Vasculature is Associated with Overexpression of Heat shock Factor 2. Gene Regulation and Systems Biology, 2010, 4, GRSB.S4546.	2.3	12
103	Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response. Endocrine-Related Cancer, 2010, 17, 215-230.	1.6	30
104	Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation study. Breast Cancer Research, 2010, 12, R103.	2.2	20
105	Ancestry-Shift Refinement Mapping of the C6orf97-ESR1 Breast Cancer Susceptibility Locus. PLoS Genetics, 2010, 6, e1001029.	1.5	82
106	Anti-Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells. Journal of the National Cancer Institute, 2009, 101, 61-66.	3.0	407
107	Relevance of Breast Cancer Antiestrogen Resistance Genes in Human Breast Cancer Progression and Tamoxifen Resistance. Journal of Clinical Oncology, 2009, 27, 542-549.	0.8	93
108	Response: Re: Antiâ€“Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells. Journal of the National Cancer Institute, 2009, 101, 896-897.	3.0	10

#	Article	IF	Citations
109	Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues. BMC Genomics, 2009, 10, 424.	1.2	74
110	Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer. Breast Cancer Research and Treatment, 2009, 116, 263-271.	1.1	35
111	The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Research and Treatment, 2009, 116, 303-309.	1.1	134
112	Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Research and Treatment, 2009, 118, 455-468.	1.1	171
113	TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer. Breast Cancer Research and Treatment, 2009, 113, 253-260.	1.1	24
114	Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature, 2009, 462, 1005-1010.	13.7	776
115	CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer. British Journal of Cancer, 2009, 101, 1824-1832.	2.9	37
116	Copy Number Alterations that Predict Metastatic Capability of Human Breast Cancer. Cancer Research, 2009, 69, 3795-3801.	0.4	75
117	Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor. Breast Cancer Research and Treatment, 2008, 111, 229-240.	1.1	55
118	DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients. Breast Cancer Research and Treatment, 2008, 111, 429-437.	1.1	103
119	Protein kinase CÎ´ expression in breast cancer as measured by real-time PCR, western blotting and ELISA. British Journal of Cancer, 2008, 99, 1644-1650.	2.9	35
120	Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer. Endocrine-Related Cancer, 2008, 15, 101-111.	1.6	59
121	Subtypes of Breast Cancer Show Preferential Site of Relapse. Cancer Research, 2008, 68, 3108-3114.	0.4	674
122	Association of an Extracellular Matrix Gene Cluster with Breast Cancer Prognosis and Endocrine Therapy Response. Clinical Cancer Research, 2008, 14, 5555-5564.	3.2	155
123	Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13021-13026.	3.3	374
124	HOXB13-to-IL17BR Expression Ratio Is Related With Tumor Aggressiveness and Response to Tamoxifen of Recurrent Breast Cancer: A Retrospective Study. Journal of Clinical Oncology, 2007, 25, 662-668.	0.8	118
125	Concentrations of TIMP1 mRNA Splice Variants and TIMP-1 Protein Are Differentially Associated with Prognosis in Primary Breast Cancer. Clinical Chemistry, 2007, 53, 1280-1288.	1.5	31
126	Circulating tumour cell detection on its way to routine diagnostic implementation?. European Journal of Cancer, 2007, 43, 2645-2650.	1.3	101

#	Article	IF	Citations
127	Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer. BMC Cancer, 2007, 7, 182.	1.1	109
128	Which Cyclin E Prevails as Prognostic Marker for Breast Cancer? Results from a Retrospective Study Involving 635 Lymph Nodeâ€"Negative Breast Cancer Patients. Clinical Cancer Research, 2006, 12, 3319-3328.	3.2	76
129	Genes Associated With Breast Cancer Metastatic to Bone. Journal of Clinical Oncology, 2006, 24, 2261-2267.	0.8	278
130	Multicenter Validation of a Gene Expressionâ€"Based Prognostic Signature in Lymph Nodeâ€"Negative Primary Breast Cancer. Journal of Clinical Oncology, 2006, 24, 1665-1671.	0.8	328
131	Association of DNA Methylation of Phosphoserine Aminotransferase with Response to Endocrine Therapy in Patients with Recurrent Breast Cancer. Cancer Research, 2005, 65, 4101-4117.	0.4	104
132	Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling. Journal of Clinical Oncology, 2005, 23, 732-740.	0.8	322
133	How ADAM-9 and ADAM-11 Differentially From Estrogen Receptor Predict Response to Tamoxifen Treatment in Patients with Recurrent Breast Cancer: a Retrospective Study. Clinical Cancer Research, 2005, 11, 7311-7321.	3.2	78
134	Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet, The, 2005, 365, 671-679.	6.3	2,452
135	Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression. Thrombosis and Haemostasis, 2003, 89, 393-404.	1.8	69